Recent studies offer new insights into ALK detection methods and related treatments. Screening for the non-small cell lung cancer (NSCLC) subtype has been at the forefront of NSCLC research, and ...
The discussion transitions to biomarker testing as an essential component of lung cancer diagnosis, with Dr. Florez ...
Circulating Human Papillomavirus DNA as a Biomarker of Response in Patients With Locally Advanced Cervical Cancer Treated With Definitive Chemoradiation Patients age ≥ 18 years with two or more visits ...
Routine testing with both fluorescent in situ hybridization and immunohistochemistry may enhance the detection of ALK-positive non-small cell lung cancer, new research suggests. Accurate determination ...
Sixteen institutions across Europe collaborated together to show for the first time that a semi-quantitative anaplastic lymphoma kinase protein expression test, immunohistochemistry, is reliable ...
Simultaneous Approval of New Treatment and Companion Diagnostic Represents Significant Advance in Personalized Medicine for Patients with Non-Small-Cell Lung Cancer Abbott Park, Illinois (NYSE: ABT) - ...
ABBOTT PARK, Ill., Oct. 24, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it will expand the current CE-IVD product labeling for its Vysis ® ALK Break Apart FISH Probe Kit, allowing the ...
Abbott announced that the FDA has approved a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC). The new ...
DENVER – Sixteen institutions across Europe collaborated together to show for the first time that a semi-quantitative anaplastic lymphoma kinase (ALK) protein expression test, immunohistochemistry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results